Topical medical therapy and ocular perfusion pressure in open angle glaucoma: a systematic review and meta-analysis

References

• Anderson DR, Drance SM, Schulzer M. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126:487–497.
   PubMed Web of Science ®Google Scholar
• Gaasterland DE, Ederer F, Beck A, et al. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429–440.
   PubMed Web of Science ®Google Scholar
• Riva CE, Hero M, Titze P, et al. Autoregulation of human optic nerve head blood flow in response to acute changes in ocular perfusion pressure. Graefe’s Arch Clin Exp Ophthalmol. 1997;235:618–626.
   PubMed Web of Science ®Google Scholar
• Harris A, Rechtman E, Siesky B, et al. The role of optic nerve blood flow in the pathogenesis of glaucoma. Ophthalmol Clin North Am. 2005;18:345–353.
   PubMedGoogle Scholar
• Nicolela MT. Clinical clues of vascular dysregulation and its association with glaucoma. Can J Ophthalmol. 2008;43:337–341.
   PubMed Web of Science ®Google Scholar
• Plange N, Kaup M, Remky A, et al. Prolonged retinal arteriovenous passage time is correlated to ocular perfusion pressure in normal tension glaucoma. Graefe’s Arch Clin Exp Ophthalmol. 2008;246:1147–1152.
   PubMed Web of Science ®Google Scholar
• Bonomi L, Marchini G, Marraffa M, et al. Vascular risk factors for primary open angle glaucoma: the Egna–Neumarkt Study. Ophthalmology. 2000;107:1287–1293.
   PubMed Web of Science ®Google Scholar
• Leske MC. Ocular perfusion pressure and glaucoma: clinical trial and epidemiologic findings. Curr Opin Ophthalmol. 2009;20:73–78.
   PubMed Web of Science ®Google Scholar
• Xu L, Wang YX, Jonas JB. Ocular perfusion pressure and glaucoma: the Beijing Eye Study. Eye (Lond). 2009;23:734–736.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Wong TY, Mitchell P, et al. Distribution of ocular perfusion pressure and its relationship with open-angle glaucoma: the Singapore Malay eye study. Invest Ophthalmol Vis Sci. 2010;51:3399–3404.
   PubMed Web of Science ®Google Scholar
• Tielsch JM, Katz J, Sommer A, et al. Hypertension, perfusion pressure, and primary open-angle glaucoma. A population-based assessment. Arch Ophthalmol. 1995;113:216.
   PubMed Web of Science ®Google Scholar
• Quigley HA, West SK, Rodriguez J, et al. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. Arch Ophthalmol. 2001;119:1819–1826.
   PubMed Web of Science ®Google Scholar
• Leske MC, Connell AM, Wu SY, et al. Risk factors for open-angle glaucoma. The Barbados Eye Study. Arch Ophthalmol. 1995;113:918–924.
   PubMed Web of Science ®Google Scholar
• Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007;114:1965–1972.
   PubMed Web of Science ®Google Scholar
• Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin–timolol fixed combinations: a meta-analysis of randomized clinical trials (provisional abstract). Eur J Ophthalmol. 2011;22(1):5–18.
   Web of Science ®Google Scholar
• Cheng J, Cai J, Wei R. Meta-analysis of medical intervention for normal tension glaucoma (structured abstract). Ophthalmology. 2009;116:1243–1249.
   PubMed Web of Science ®Google Scholar
• Orme M, Collins S, Dakin H, et al. Mixed treatment comparison and meta-regression of the efficacy and safety of prostaglandin analogues and comparators for primary open-angle glaucoma and ocular hypertension. Curr Med Res Opin. 2010;26:511–528.
   PubMed Web of Science ®Google Scholar
• Vass C, Hirn C, Sycha T, et al. Medical interventions for primary open angle glaucoma and ocular hypertension. Cochrane Database Syst Rev. 2007;4:CD003167. DOI:10.1002/14651858.CD003167.pub3
   Google Scholar
• Detry-Morel M. Side effects of glaucoma medications. Bull Soc Belge Ophtalmol. 2006;299:27–40.
   Google Scholar
• Hayreh SS, Podhajsky P, Zimmerman MB. Beta-blocker eyedrops and nocturnal arterial hypotension. Am J Ophthalmol. 1999;128:301–309.
   PubMed Web of Science ®Google Scholar
• Krupin T, Liebmann JM, Greenfield DS, et al. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol. 2011;151:671–681.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg (London, England). 2010;8:336–341.
   PubMed Web of Science ®Google Scholar
• Costa VP, Harris A, Anderson D, et al. Ocular perfusion pressure in glaucoma. Acta Ophthalmol. 2014;92:e252–e266.
   PubMed Web of Science ®Google Scholar
• Costagliola C, Parmeggiani F, Virgili G, et al. Circadian changes of intraocular pressure and ocular perfusion pressure after timolol or latanoprost in Caucasians with normal-tension glaucoma. Graefe’s Arch Clin Exp Ophthalmol. 2008;246:389–396.
   PubMed Web of Science ®Google Scholar
• Fuchsjäger-Mayrl G, Wally B, Rainer G, et al. Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension. Br J Ophthalmol. 2005;89:1293–1297.
   PubMed Web of Science ®Google Scholar
• Harris A, Migliardi R, Rechtman E, et al. Comparative analysis of the effects of dorzolamide and latanoprost on ocular hemodynamics in normal tension glaucoma patients. Eur J Ophthalmol. 2003;13:24–31.
   PubMed Web of Science ®Google Scholar
• Inan U, Ermis S, Yücel A, et al. The effects of latanoprost and brimonidine on blood flow velocity of the retrobulbar vessels: a 3-month clinical trial. Acta Ophthalmol Scand. 2003;81:155–160.
   PubMedGoogle Scholar
• Liu C, Ko Y, Cheng C, et al. Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients. Ophthalmology. 2002;109:2241–2247.
   PubMed Web of Science ®Google Scholar
• Liu CJL, Cheng CY, Ko YC, et al. Diurnal intraocular pressure and blood pressure with two dosing regimens of brimonidine in normal tension glaucoma. J Chin Med Assoc. 2004;67:465–471.
   PubMedGoogle Scholar
• Oddone F, Rossetti L, Tanga L, et al. Effects of topical bimatoprost 0.01% and timolol 0.5% on circadian IOP, blood pressure and perfusion pressure in patients with glaucoma or ocular hypertension: a randomized, double masked, placebo-controlled clinical trial. PLoS One. 2015;10:e0140601.
   PubMed Web of Science ®Google Scholar
• Quaranta L, Katsanos A, Floriani I, et al. Circadian intraocular pressure and blood pressure reduction with timolol 0.5% solution and timogel 0.1% in patients with primary open-angle glaucoma. J Clin Pharmacol. 2012;52:1552–1557.
   PubMed Web of Science ®Google Scholar
• Quaranta L, Miglior S, Floriani I, et al. Effects of the timolol–dorzolamide fixed combination and latanoprost on circadian diastolic ocular perfusion pressure in glaucoma. Invest Ophthalmol Vis Sci. 2008;49:4226–4231.
   PubMed Web of Science ®Google Scholar
• Shin J, Lee JW, Choi BS, et al. The circadian changes of intraocular pressure and ocular perfusion pressure after tafluprost compared with travoprost in normal tension glaucoma. J Ocul Pharmacol Ther. 2014;30:803–809.
   PubMed Web of Science ®Google Scholar
• Lin L, Zhao Y, Chew P, et al. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension (provisional abstract). Ann Pharmacother. 2014;48(12):1585–1593.
   PubMed Web of Science ®Google Scholar
• Denis P, Lafuma A, Khoshnood B, et al. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy. Curr Med Res Opin. 2007;23:601–608.
   PubMed Web of Science ®Google Scholar
• Kawaguchi I, Higashide T, Ohkubo S, et al. Comparison of efficacy of four prostaglandin analogues by bilateral treatment in healthy subjects. Jpn J Ophthalmol. 2012;56:346–353.
   PubMed Web of Science ®Google Scholar
• Mishra D, Sinha BP, Kumar MS. Comparing the efficacy of latanoprost (0.005%), bimatoprost (0.03%), travoprost (0.004%), and timolol (0.5%) in the treatment of primary open angle glaucoma. Korean J Ophthalmol. 2014;28:399–407.
   PubMedGoogle Scholar
• Stalmans I, Oddone F, Cordeiro MF, et al. Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial. Graefe’s Arch Clin Exp Ophthalmol. 2016;254:1151–1158.
   PubMed Web of Science ®Google Scholar
• Li T, Lindsley K, Rouse B, et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis. Ophthalmology. 2016;123:129–140.
   PubMed Web of Science ®Google Scholar
• Stewart WC, Konstas AG, Kruft B, et al. Meta-analysis of 24-h intraocular pressure fluctuation studies and the efficacy of glaucoma medicines. J Ocul Pharmacol Ther. 2010;26:175–180.
   PubMed Web of Science ®Google Scholar
• Inoue K, Setogawa A, Tomita G. Nonresponders to prostaglandin analogs among normal-tension glaucoma patients. J Ocul Pharmacol Ther. 2016;32:90–96.
   PubMed Web of Science ®Google Scholar
• Rossetti L, Sacchi M, Karabatsas CH, et al. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on 24-hour blood and ocular perfusion pressures: the results of a randomized trial. BMC Ophthalmol. 2015;15:7.
   PubMed Web of Science ®Google Scholar
• Inan UU, Ermis SS, Orman A, et al. The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical travoprost, bimatoprost, brimonidine, and betaxolol. J Ocul Pharmacol Ther. 2004;20:293–310.
   PubMed Web of Science ®Google Scholar
• Arend O, Harris A, Arend S, et al. The acute effect of topical beta-adrenoreceptor blocking agents on retinal and optic nerve head circulation. Acta Ophthalmol Scand. 1998;76:43–49.
   PubMed Web of Science ®Google Scholar
• Uusitalo H, Nino J, Tahvanainen K, et al. Efficacy and systemic side-effects of topical 0.5% timolol aqueous solution and 0.1% timolol hydrogel. Acta Ophthalmol Scand. 2005;83:723–728.
   PubMedGoogle Scholar
• Dickstein K, Aarsland T. Comparison of the effects of aqueous and gellan ophthalmic timolol on peak exercise performance in middle-aged men. Am J Ophthalmol. 1996;121:367–371.
   PubMed Web of Science ®Google Scholar
• Korte JM, Kaila T, Saari KM. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. Graefe’s Arch Clin Exp Ophthalmol. 2002;240:430–435.
   PubMed Web of Science ®Google Scholar
• Stewart WC, Stewart JA, Crockett S, et al. Comparison of the cardiovascular effects of unoprostone 0.15%, timolol 0.5% and placebo in healthy adults during exercise using a treadmill test. Acta Ophthalmol Scand. 2002;80:272–276.
   PubMedGoogle Scholar
• Nieminen T, Uusitalo H, Turjanmaa V, et al. Association between low plasma levels of ophthalmic timolol and haemodynamics in glaucoma patients. Eur J Clin Pharmacol. 2005;61:369–374.
   PubMed Web of Science ®Google Scholar
• Lee PW, Doyle A, Stewart JA, et al. Meta-analysis of timolol on diurnal and nighttime intraocular pressure and blood pressure. Eur J Ophthalmol. 2010;20:1035–1041.
   PubMed Web of Science ®Google Scholar
• Daka Q, Trkulja V. Efficacy and tolerability of mono-compound topical treatments for reduction of intraocular pressure in patients with primary open angle glaucoma or ocular hypertension: an overview of reviews. Croat Med J. 2014;55:468–480.
   PubMed Web of Science ®Google Scholar
• Raber S, Mandema JW, Li H, et al. Model-based dose–response meta-analysis of ocular hypotensive agents as a drug development tool to evaluate new therapies in glaucoma. J Ocul Pharmacol Ther. 2015;31:189–197.
   PubMed Web of Science ®Google Scholar
• Sit AJ. Intraocular pressure variations: causes and clinical significance. Can J Ophthalmol. 2014;49:484–488.
   PubMed Web of Science ®Google Scholar
• Drance SM, Crichton A, Mills RP. Comparison of the effect of latanoprost 0.005% and timolol 0.5% on the calculated ocular perfusion pressure in patients with normal-tension glaucoma. Am J Ophthalmol. 1998;125:585–592.
   PubMed Web of Science ®Google Scholar
• Quaranta L, Gandolfo F, Turano R, et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci. 2006;47:2917–2923.
   PubMed Web of Science ®Google Scholar
• Arend O, Harris A, Wolter P, et al. Evaluation of retinal haemodynamics and retinal function after application of dorzolamide, timolol and latanoprost in newly diagnosed open-angle glaucoma patients. Acta Ophthalmol Scand. 2003;81:474–479.
   PubMedGoogle Scholar
• Nicolela MT, Buckley AR, Walman BE, et al. A comparative study of the effects of timolol and latanoprost on blood flow velocity of the retrobulbar vessels. Am J Ophthalmol. 1996;122:784–789.
   PubMed Web of Science ®Google Scholar
• Maier PC, Funk J, Schwarzer G, et al. Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. BMJ (Clin Res Ed). 2005;331:134.
   PubMed Web of Science ®Google Scholar
• Honrubia F, Garcia-Sanchez J, Polo V, et al. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. Br J Ophthalmol. 2009;93:316–321.
   PubMed Web of Science ®Google Scholar
• Vass C, Hirn C, Sycha T, et al. Medical interventions for primary open angle glaucoma and ocular hypertension. Cochrane Database Syst Rev. 2007;17:Cd003167.
   Google Scholar